cropped-user_picto22.png

Master 2 Santé publique spécialité Recherche clinique

Statisticienne

2014

Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, Neau D, Cazanave C, Pellegrin JL, Dabis F, Morlat P, Chêne G; GECSA study group. Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort. PLoS One. 2014 Jul 30;9(7):e102671. doi: 10.1371/journal.pone.0102671. eCollection 2014.

2013

Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d’Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013 Oct;57(7):1038-47. doi: 10.1093/cid/cit423.

Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS139 TRIO Trial study group. Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial). PLoS One. 2013;8(1):e53621. doi: 10.1371/journal.pone.0053621.

2012

Goujard C, Emilie D, Roussillon C, Godot V, Rouzioux C, Venet A, Colin C, Pialoux G, Girard PM, Boilet V, Chaix ML, Galanaud P, Chene G; ANRS-112 INTERPRIM Study Group. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS. 2012 Sep 24;26(15):1895-905.

Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y; ANRS 139 TRIO Trial Group. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93. doi: 10.1097/QAI.0b013e31824bb720.

Pursuing Later Treatment Options II (PLATO II) project team; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group, Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, De Wit S, Stephan C, Obel N, Fätkenhaeuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9. doi: 10.1097/QAI.0b013e31823fe66b.

Pursuing Later Treatment Option II (PLATO II) project team; Observational HIV Epidemiological Research Europe (COHERE) Group, Castagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, Garcia F, Zangerle R, Duval X, Pérez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Fabre-Colin C, Kjaer J, Grarup J, Costagliola D, Lodwick R, Ledergerber B, Phillips A. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis. 2012 Feb;12(2):119-27. doi: 10.1016/S1473-3099(11)70248-1. Epub 2011 Oct 9.

2011

Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet. 2011 May 7;377(9777):1546-8.

Linda Wittkop, Huldrych F Günthard, Frank de Wolf, David Dunn, Alessandro Cozzi-Lepri, Andrea de Luca, Claudia Kücherer, Niels Obel, Viktor von Wyl, Bernard Masquelier, Christoph Stephan, Carlo Torti, Andrea Antinori, Federico García, Ali Judd, Kholoud Porter, Rodolphe Thiébaut, Hannah Castro, Ard I van Sighem, Céline Colin, Jesper Kjaer, Jens D Lundgren, Roger Paredes, Anton Pozniak, Bonaventura Clotet, Andrew Phillips, Deenan Pillay*, Geneviève Chêne*, for the EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011 Feb 25

2010

Barrail-Tran, Aurélie; Yazdanpanah, Yazdan; Goldwirt, Lauriane; Chêne, Geneviève; Colin, Céline; Piketty, Christophe; Bollens, Diane; Katlama, Christine; Descamps, Diane; Molina, Jean-Michel; Fagard, Catherine; Taburet, Anne-Marie; and ANRS 139 study group. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. AIDS 2010, 24:2581–2593

Charpentier, Charlotte; Roquebert, Bénédicte; Colin, Céline; Taburet, Anne-Marie; Fagard, Catherine; Katlama, Christine; Molina, Jean-Michel; Jacomet, Christine; Brun-Vézinet, Françoise; Chêne, Geneviève; Yazdanpanah, Yazdan; Descamps, Diane; the ANRS 139 TRIO Trial study group. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. AIDS. 2010 Aug 26

2009

Y Yazdanpanah, C Fagard, D Descamps, AM Taburet, C Colin, B. Roquebert, C Katlama, G Pialoux, C Jacomet, C Piketty, D Bollens, JM Molina, G Chene and the ANRS 139 TRIO Trial Group. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir in multidrug-resistant treatment-experienced HIV-infected patients: Results of the ANRS 139 TRIO trial. CID. 2009 Nov 1; 49(9):1441-9

2007

Laura Adalid-Peralta, Véronique Godot, Céline Colin, Roman Krzysiek, Thi Tran, Pascal Poignard, Alain Venet, Anne Hosmalin, Pierre Lebon, Christine Rouzioux, Genevieve Chene, Dominique Emilie the Interprim ANRS 112 Study Group. Stimulation of the primary anti-HIV antibody response by IFN- in patients with acute HIV-1 infection.J. Leukoc. Biol. 2008 83: 1060-1067.

2006

Campone M, Cortes-Funes H, Vorobiof D, Martin M, Slabber CF, Ciruelos E, Bourbouloux E, Mendiola C, Delgado FM, Colin C, Aslanis V, Fumoleau P.Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer. 2006 Nov 6;95(9):1161-6.

Bennouna J, Breton JL, Tourani JM, Ottensmeier C, O’Brien M, Kosmidis P, Huat TE, Pinel MC, Colin C, Douillard JY. Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer. 2006 May 22;94(10):1383-8.

2005

Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.Lung Cancer. 2005 Apr;48(1):129-35.

Carles Galcerán J, Bastus Piulats R, Martín-Broto J, Maroto Rey P, Nogué Aligué M, Domenech Santasusana M, Arcusa Lanza A, Bellmunt Molins J, Colin C, Girard A. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. Clin Transl Oncol. 2005 Mar;7(2):66-73.

logo_ISPED logo_Université-de-Bordeaux logo_SFR-santepublique-societe logo_CHU-Bordeaux logo_Institut-Bergonie logo_INRIA logo_ANRS logo_ARS logo_Charles-Perrens logo_IFSTTAR logo_HONcode